Literature DB >> 25896749

Selecting anti-microbial treatment of aerobic vaginitis.

Gilbert G G Donders1, Katerina Ruban, Gert Bellen.   

Abstract

Aerobic vaginitis (AV) is a vaginal infectious condition which is often confused with bacterial vaginosis (BV) or with the intermediate microflora as diagnosed by Nugent's method to detect BV on Gram-stained specimens. However, although both conditions reflect a state of lactobacillary disruption in the vagina, leading to an increase in pH, BV and AV differ profoundly. While BV is a noninflammatory condition composed of a multiplex array of different anaerobic bacteria in high quantities, AV is rather sparely populated by one or two enteric commensal flora bacteria, like Streptococcus agalactiae, Staphylocuccus aureus, or Escherichia coli. AV is typically marked by either an increased inflammatory response or by prominent signs of epithelial atrophy or both. The latter condition, if severe, is also called desquamative inflammatory vaginitis. As AV is per exclusionem diagnosed by wet mount microscopy, it is a mistake to treat just vaginal culture results. Vaginal cultures only serve as follow-up data in clinical research projects and are at most used in clinical practice to confirm the diagnosis or exclude Candida infection. AV requires treatment based on microscopy findings and a combined local treatment with any of the following which may yield the best results: antibiotic (infectious component), steroids (inflammatory component), and/or estrogen (atrophy component). In cases with Candida present on microscopy or culture, antifungals must be tried first in order to see if other treatment is still needed. Vaginal rinsing with povidone iodine can provide rapid relief of symptoms but does not provide long-term reduction of bacterial loads. Local antibiotics most suitable are preferably non-absorbed and broad spectrum, especially those covering enteric gram-positive and gram-negative aerobes, like kanamycin. To achieve rapid and short-term improvement of severe symptoms, oral therapy with amoxyclav or moxifloxacin can be used, especially in deep dermal vulvitis and colpitis infections with group B streptococci or (methicillin resistant) Staphylococcus aureus. Since the latter colonizations are frequent, but seldom inflammatory infections, we in general discourage the use of oral antibiotics in women with AV. In cases with a severe atrophy component (more than 10 % of epithelial cells are of the parabasal type), local estrogens can be used; and in postmenopausal or breast cancer patients with a contraindication for estrogens, even a combination of probiotics with an ultra-low dose of local estriol may be considered.

Entities:  

Year:  2015        PMID: 25896749     DOI: 10.1007/s11908-015-0477-6

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  63 in total

1.  Effect of lyophilized lactobacilli and 0.03 mg estriol (Gynoflor®) on vaginitis and vaginosis with disrupted vaginal microflora: a multicenter, randomized, single-blind, active-controlled pilot study.

Authors:  G G G Donders; B Van Bulck; P Van de Walle; R R Kaiser; G Pohlig; S Gonser; F Graf
Journal:  Gynecol Obstet Invest       Date:  2010-10-16       Impact factor: 2.031

Review 2.  Desquamative inflammatory vaginitis.

Authors:  Orna Reichman; Jack Sobel
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2014-07-17       Impact factor: 5.237

3.  [Clinical characteristics of aerobic vaginitis and its mixed infections].

Authors:  Ai-Ping Fan; Feng-Xia Xue
Journal:  Zhonghua Fu Chan Ke Za Zhi       Date:  2010-12

Review 4.  Clindamycin, metronidazole, and chloramphenicol.

Authors:  M J Kasten
Journal:  Mayo Clin Proc       Date:  1999-08       Impact factor: 7.616

5.  Efficacy of povidone-iodine vaginal suppositories in the treatment of bacterial vaginosis.

Authors:  Günther Wewalka; Angelika Stary; Bjoern Bosse; Heike E Duerr; Karen Reimer
Journal:  Dermatology       Date:  2002       Impact factor: 5.366

6.  Correlation of local interleukin-1beta levels with specific IgA response against Gardnerella vaginalis cytolysin in women with bacterial vaginosis.

Authors:  Sabina Cauci; Silvia Driussi; Secondo Guaschino; Miriam Isola; Franco Quadrifoglio
Journal:  Am J Reprod Immunol       Date:  2002-05       Impact factor: 3.886

7.  Vaginal cytokines in normal pregnancy.

Authors:  Gilbert G G Donders; Annie Vereecken; Eugene Bosmans; Bernard Spitz
Journal:  Am J Obstet Gynecol       Date:  2003-11       Impact factor: 8.661

Review 8.  Desquamative inflammatory vaginitis.

Authors:  Ruth Murphy
Journal:  Dermatol Ther       Date:  2004       Impact factor: 2.851

9.  Intravaginal clindamycin to reduce preterm birth in women with abnormal genital tract flora.

Authors:  Ronald F Lamont; Sheila L B Duncan; Debashis Mandal; Paul Bassett
Journal:  Obstet Gynecol       Date:  2003-03       Impact factor: 7.661

10.  Impairment of the mucosal immune system: IgA and IgM cleavage detected in vaginal washings of a subgroup of patients with bacterial vaginosis.

Authors:  S Cauci; R Monte; S Driussi; P Lanzafame; F Quadrifoglio
Journal:  J Infect Dis       Date:  1998-12       Impact factor: 5.226

View more
  9 in total

1.  Abnormal vaginal flora in symptomatic non-pregnant and pregnant women in a Greek hospital: a prospective study.

Authors:  G S Tansarli; T Skalidis; N J Legakis; M E Falagas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-10-13       Impact factor: 3.267

2.  Long lasting mucoadhesive membrane based on alginate and chitosan for intravaginal drug delivery.

Authors:  Fabio Tentor; Giorgia Siccardi; Pasquale Sacco; Danilo Demarchi; Eleonora Marsich; Kristoffer Almdal; Sanjukta Bose Goswami; Anja Boisen
Journal:  J Mater Sci Mater Med       Date:  2020-02-14       Impact factor: 3.896

3.  An unusual case of recurrent vaginal discharge: Diagnostic and therapeutic dilemma.

Authors:  Meenu Malik; Taru Garg; Ram Chander
Journal:  Indian J Sex Transm Dis AIDS       Date:  2022-06-07

4.  Abnormal vaginal microbioma is associated with severity of localized provoked vulvodynia. Role of aerobic vaginitis and Candida in the pathogenesis of vulvodynia.

Authors:  Gilbert G G Donders; Gert Bellen; Kateryna S Ruban
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-06-22       Impact factor: 3.267

5.  The Evolving Facets of Bacterial Vaginosis: Implications for HIV Transmission.

Authors:  Lyle R McKinnon; Sharon L Achilles; Catriona S Bradshaw; Adam Burgener; Tania Crucitti; David N Fredricks; Heather B Jaspan; Rupert Kaul; Charu Kaushic; Nichole Klatt; Douglas S Kwon; Jeanne M Marrazzo; Lindi Masson; R Scott McClelland; Jacques Ravel; Janneke H H M van de Wijgert; Lenka A Vodstrcil; Gilda Tachedjian
Journal:  AIDS Res Hum Retroviruses       Date:  2019-03       Impact factor: 2.205

Review 6.  Microbiota in vaginal health and pathogenesis of recurrent vulvovaginal infections: a critical review.

Authors:  Namarta Kalia; Jatinder Singh; Manpreet Kaur
Journal:  Ann Clin Microbiol Antimicrob       Date:  2020-01-28       Impact factor: 3.944

Review 7.  Vaginal microbiota and the potential of Lactobacillus derivatives in maintaining vaginal health.

Authors:  Wallace Jeng Yang Chee; Shu Yih Chew; Leslie Thian Lung Than
Journal:  Microb Cell Fact       Date:  2020-11-07       Impact factor: 5.328

8.  Therapeutic effects of silver nanoparticle and L-carnitine on aerobic vaginitis in mice: an experimental study.

Authors:  Mozhgan Fatahi Dehpahni; Khosrow Chehri; Mehri Azadbakht
Journal:  Bioimpacts       Date:  2021-10-25

Review 9.  Vaginal Microbiomes Associated With Aerobic Vaginitis and Bacterial Vaginosis.

Authors:  Evelyn Kaambo; Charlene Africa; Ramadhani Chambuso; Jo-Ann Shelley Passmore
Journal:  Front Public Health       Date:  2018-03-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.